GlassScriptPhysician profile
Mayda Melendez
NPI 1760491807
$11,995.05
in general payments reported to CMS, 2019-2025
39 companies · $1,993 in 2025
The $1,993 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,741 · 2020: $1,202 · 2021: $1,597 · 2022: $1,589 · 2023: $1,799 · 2024: $2,074 · 2025: $1,993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,614 · Education: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,614.05 |
| Education | $252.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,858.78 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,259.87 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,021.75 | 2019-2025 | Xifaxan, Relistor |
| Lilly USA, LLC | $978.41 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $796.81 | 2019-2025 | Jardiance |
| Pfizer INC. | $787.79 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $513.01 | 2019-2025 | Austedo Xr, Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $389.48 | 2021 | |
| Astellas Pharma US INC | $357.05 | 2023-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $348.26 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Sanofi-Aventis U.S. LLC | $328.78 | 2019-2023 | |
| Abbvie INC. | $290.38 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $234.10 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $224.57 | 2022-2025 | Seglentis, Livalo, Zoryve |
| Amgen INC. | $215.24 | 2021-2025 | Evenity, Prolia |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $206.85 | 2019 | |
| Glaxosmithkline, LLC. | $162.58 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $147.22 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ardelyx, INC. | $143.45 | 2024-2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $96.05 | 2023-2024 | |
| Tactile Systems Technology INC | $80.59 | 2024-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Alkermes, INC. | $74.89 | 2024 | Vivitrol |
| Sanofi Pasteur INC. | $43.93 | 2019-2025 | |
| Redhill Biopharma INC. | $43.26 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $37.45 | 2025 | Abilify Maintena, Rexulti |
| Mannkind Corporation | $37.39 | 2020 | |
| Phathom Pharmaceuticals, INC. | $35.60 | 2024-2025 | Voquezna |
| Lundbeck LLC | $35.29 | 2024-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $34.01 | 2023 | Quviviq |
| Neurocrine Biosciences, INC. | $30.42 | 2025 | |
| Seqirus USA INC | $25.22 | 2019-2020 | |
| Pharmacosmos Therapeutics INC. | $25.00 | 2022 | |
| Smith+Nephew, INC. | $23.34 | 2023 | Regranex, Collagenase Santyl |
| Bayer Healthcare Pharmaceuticals INC. | $22.28 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $21.04 | 2025 | Dupixent |
| Eisai INC. | $17.58 | 2021 | |
| Endo Pharmaceuticals INC. | $15.93 | 2022 | |
| Cipher Pharmaceuticals US LLC | $15.92 | 2025 | Natroba, Spinosad |
| Vbi Vaccine (Delaware) INC. | $15.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mayda Melendez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.